AR060278A1 - Tratamientos de las alergias oculares - Google Patents

Tratamientos de las alergias oculares

Info

Publication number
AR060278A1
AR060278A1 ARP070101408A ARP070101408A AR060278A1 AR 060278 A1 AR060278 A1 AR 060278A1 AR P070101408 A ARP070101408 A AR P070101408A AR P070101408 A ARP070101408 A AR P070101408A AR 060278 A1 AR060278 A1 AR 060278A1
Authority
AR
Argentina
Prior art keywords
eye allergy
allergy treatments
treatments
eye
alcaftadine
Prior art date
Application number
ARP070101408A
Other languages
English (en)
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060278(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of AR060278A1 publication Critical patent/AR060278A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones, kits y métodos para el tratamiento o prevencion de las alergias e inflamacion oculares y los síntomas de las mismas, que comprenden alcaftadina o una sal farmacéuticamente aceptable de la misma.
ARP070101408A 2006-03-31 2007-04-03 Tratamientos de las alergias oculares AR060278A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
AR060278A1 true AR060278A1 (es) 2008-06-04

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101408A AR060278A1 (es) 2006-03-31 2007-04-03 Tratamientos de las alergias oculares

Country Status (30)

Country Link
US (7) US8664215B2 (es)
EP (2) EP3150209B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK3150209T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2594655T3 (es)
HK (1) HK1131331A1 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL2004196T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI578990B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150209B1 (en) 2006-03-31 2019-07-24 Vistakon Pharmaceuticals, LLC Ocular allergy treatments
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
MX2010005012A (es) * 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
EP3943069A1 (en) 2009-03-17 2022-01-26 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
KR20200035047A (ko) * 2017-08-03 2020-04-01 산텐 세이야꾸 가부시키가이샤 클로르헥시딘을 함유하는 의약 조성물
WO2019141563A1 (en) * 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
AU2021291684A1 (en) 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
JP2024508811A (ja) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド 小管内デポーインサータ装置
KR20230163413A (ko) 2021-04-01 2023-11-30 알켐 라보라토리즈 리미티드 알카프타딘을 포함하는 비강 조성물
WO2024010044A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
TW202408472A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) * 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
AU8902591A (en) * 1990-10-10 1992-05-20 Schering Corporation Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
US20070077302A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
EP2010143B1 (en) 2006-03-17 2015-08-12 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
EP3150209B1 (en) 2006-03-31 2019-07-24 Vistakon Pharmaceuticals, LLC Ocular allergy treatments

Also Published As

Publication number Publication date
JP5292277B2 (ja) 2013-09-18
TWI578990B (zh) 2017-04-21
US20170065605A1 (en) 2017-03-09
EP3150209A1 (en) 2017-04-05
TW200815016A (en) 2008-04-01
KR20080110881A (ko) 2008-12-19
HK1131331A1 (en) 2010-01-22
NZ571690A (en) 2011-09-30
CA2648115A1 (en) 2007-10-18
KR101321731B1 (ko) 2013-10-30
MY153669A (en) 2015-03-13
EA016221B1 (ru) 2012-03-30
AU2007234957A1 (en) 2007-10-18
PL2004196T3 (pl) 2017-01-31
SG170044A1 (en) 2011-04-29
CR10414A (es) 2009-02-23
BRPI0710085B1 (pt) 2019-12-17
ECSP088786A (es) 2009-01-30
ES2752823T3 (es) 2020-04-06
WO2007117971A2 (en) 2007-10-18
CL2007000916A1 (es) 2008-01-25
EA200870396A1 (ru) 2009-04-28
DK2004196T3 (en) 2016-09-05
MX2008012657A (es) 2009-02-19
BRPI0710085B8 (pt) 2021-05-25
DK3150209T3 (da) 2019-10-28
JP2013144703A (ja) 2013-07-25
AU2007234957B2 (en) 2012-12-13
EP3150209B1 (en) 2019-07-24
JP2009533333A (ja) 2009-09-17
US8664215B2 (en) 2014-03-04
EP2004196B1 (en) 2016-06-29
JP2015131820A (ja) 2015-07-23
TW201446249A (zh) 2014-12-16
US20210030762A1 (en) 2021-02-04
US20080051385A1 (en) 2008-02-28
IL194473A (en) 2016-04-21
US20120094978A1 (en) 2012-04-19
BRPI0710085A2 (pt) 2011-08-23
NO341147B1 (no) 2017-09-04
EP2004196A2 (en) 2008-12-24
UY30254A1 (es) 2007-08-31
JO3358B1 (ar) 2019-03-13
IL194473A0 (en) 2009-08-03
PE20080053A1 (es) 2008-03-10
US20240058355A1 (en) 2024-02-22
NO20084593L (no) 2008-10-29
CA2648115C (en) 2015-03-24
WO2007117971A3 (en) 2007-12-27
CN102895234A (zh) 2013-01-30
TWI450721B (zh) 2014-09-01
NI200800261A (es) 2012-10-30
US20140107102A1 (en) 2014-04-17
PL3150209T3 (pl) 2020-03-31
US10617695B2 (en) 2020-04-14
ZA200809327B (en) 2009-12-30
JP6039716B2 (ja) 2016-12-07
ES2594655T3 (es) 2016-12-21
US20230181594A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CR10414A (es) Tratamientos de las alergias oculares
CR10347A (es) Anticuerpos contra el peptidob-amiloide
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
CR10226A (es) Combinaciones del inhibidor de ang2 y vegf
EA200901211A1 (ru) Антигены белка с5 и их применение
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR9580A (es) Inhibidores de la actividad akt
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
SV2009002863A (es) Compuestos anti-hipercolesterolemicos
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas

Legal Events

Date Code Title Description
FC Refusal